Lessons to learn from the COX-2 saga
Yes, FDA reforms are needed. And marketing distorts how medications are used. But one moral to the story is that all drugs have risks.
The bad news for the COX-2 pain relievers started in September 2004. Rofecoxib (Vioxx) was pulled from the market after a study testing whether the pain reliever could prevent colon polyps instead showed that it doubled heart attack and stroke risk.